Will regulators catch up in 2020?
Rationalising pharma trade margins seems next on the list
Lupin sells stakes in Kyowa but its not a Sayonara
After sartans and ranitidine, where will NDMA show up next?
Slaying GMP non-compliance woes
Heeding the clarion call for sustainability
Price caps are a band aid hiding larger issues
CDSCO is blowin’ in the wind
Big Pharma to get bigger, but what about patients?
Protect IP to grow GDP
Page 1 of 14
Page 2 of 14
Page 14 of 14